|
Real-time Estimate
Cboe BZX
01:28:33 05/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 829.08 USD | -1.71% |
|
+4.25% | +7.26% |
| Market Cap | 8.42TCr 7.25TCr 6.82TCr 6.23TCr 12TCr 7,95200Cr 12TCr 81TCr 31TCr 4,08000Cr 32TCr 31TCr 13,14400Cr | P/E 2026 * |
19.5x | P/E 2027 * | 16.7x |
|---|---|---|---|---|---|
| Enterprise Value | 7.74TCr 6.66TCr 6.26TCr 5.72TCr 11TCr 7,30400Cr 11TCr 74TCr 29TCr 3,74700Cr 29TCr 28TCr 12,07200Cr | EV / Sales 2026 * |
4.57x | EV / Sales 2027 * | 4x |
| Free-Float |
71.06% | Yield 2026 * |
0.46% | Yield 2027 * | 0.53% |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| REGN | Delayed | |
CBOE
| REGN | Real-time | |
|
Xetra
| RGO | End-of-day quote | |
|
Tradegate
| RGO | Real-time | |
|
Boerse Muenchen
| RGO | Real-time | |
|
Mexican S.E.
| REGN * | End-of-day quote | |
|
London S.E.
| 0R2M | Delayed | |
|
Deutsche Boerse AG
| RGO | Delayed | |
|
Wiener Boerse
| REGN | End-of-day quote | |
|
Börse Stuttgart
| RGO | Delayed | |
|
Borsa Italiana
| 1REGN | End-of-day quote | |
|
Lima
| REGNUS | End-of-day quote |
Last Transcript : Regeneron Pharmaceuticals, Inc.
| 1 day | -1.69% | ||
| 1 week | +4.25% | ||
| Current month | +3.61% | ||
| 1 month | +8.84% | ||
| 3 months | +31.68% | ||
| 6 months | +5.13% | ||
| Current year | +7.26% |
| 1 week | 779.08 |  | 859.34 |
| 1 month | 762.78 | | 859.34 |
| Current year | 591.52 | | 859.34 |
| 1 year | 541 | | 859.34 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 19/08/26 | Exercice | General Counsel | 33,583 | 0.0326% | ||
| 18/08/26 | Exercice | Chief Financial Officer | 17,165 | 0.0167% | ||
| 10/08/26 | Exercice | Director | 1,200 | 0.0012% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.71% | +4.25% | +45.96% | +0.61% | 8.42TCr | |
| -0.57% | +0.36% | -15.55% | -35.15% | 6.05TCr | |
| -2.11% | +5.95% | +502.14% | +33.69% | 5.94TCr | |
| -2.03% | -9.22% | -7.00% | +28.39% | 5.03TCr | |
| -4.58% | -5.09% | +4.26% | +153.55% | 4.89TCr | |
| -1.66% | +1.07% | +57.80% | -17.07% | 3.32TCr | |
| -0.99% | +2.12% | +48.65% | +100.71% | 2.59TCr | |
| -0.19% | -4.83% | -4.30% | +191.74% | 2.28TCr | |
| -1.13% | -2.45% | +65.99% | +110.75% | 1.67TCr | |
| -0.88% | -3.15% | +43.13% | +150.46% | 1.47TCr | |
| Average | -1.63% | -0.40% | +74.11% | +71.77% | 4.17TCr | |
| Weighted average by Cap. | -1.82% | +0.71% | +89.87% | +46.44% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.69TCr 1.46TCr 1.37TCr 1.25TCr 2.34TCr 1,59800Cr 2.35TCr 16TCr 6.28TCr 82TCr 6.35TCr 6.22TCr 2,64100Cr | 1.84TCr 1.58TCr 1.49TCr 1.36TCr 2.55TCr 1,73900Cr 2.56TCr 18TCr 6.84TCr 89TCr 6.92TCr 6.77TCr 2,87400Cr |
| Net income | 477.34Cr 410.75Cr 386.46Cr 353.03Cr 660.41Cr 45TCr 662.21Cr 4.57TCr 1.77TCr 23TCr 1.79TCr 1.75TCr 74TCr | 544.54Cr 468.58Cr 440.86Cr 402.73Cr 753.39Cr 51TCr 755.44Cr 5.21TCr 2.02TCr 26TCr 2.04TCr 2TCr 85TCr |
| Net Debt | -686.84Cr -591.02Cr -556.07Cr -507.97Cr -950.26Cr -65TCr -952.85Cr -6.57TCr -2.55TCr -33TCr -2.58TCr -2.52TCr -1,07200Cr | -1.06TCr -908.16Cr -854.45Cr -780.54Cr -1.46TCr -1LCr -1.46TCr -10TCr -3.92TCr -51TCr -3.96TCr -3.88TCr -1,64700Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/26/05 | $827.93 | -1.84% | 2,67,823 |
| 03/26/03 | $843.47 | -1.00% | 4,96,255 |
| 02/26/02 | $852.03 | +3.42% | 7,49,453 |
| 01/26/01 | $823.82 | +3.10% | 6,82,806 |
| 31/26/31 | $799.08 | +0.62% | 8,94,268 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
